SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
NexImmune, Inc. (NEXI) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+3329900%).
- Analyst consensus target $3.33 (+3329900% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 63/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NEXI
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-30.82
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$3.33 (+3329900%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-14.25 |
$0.00 |
$-12.83M |
- |
| 2019 |
$-22.53 |
$0.00 |
$-20.3M |
- |
| 2020 |
$-34.76 |
$0.00 |
$-31.64M |
- |
| 2021 |
$-56.67 |
$0.00 |
$-51.75M |
- |
| 2022 |
$534.29 |
$0.00 |
$514.18M |
- |
| 2023 |
$-30.82 |
$0.00 |
$-32.34M |
- |
